Vimarsana
Biggest News Aggregation in the World

Page 47 - Breakthrough Therapy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Breakthrough Therapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Breakthrough Therapy Today - Breaking & Trending Today

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine - Vimarsana News

Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine

Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov. 17, 2023 -- Day One Biopharmaceuticals , a clinical-stage...

Valneva single-dose chikungunya vaccine poised to 'revolutionize' global health - Vimarsana News

Valneva single-dose chikungunya vaccine poised to 'revolutionize' global health

Valneva recently received the greenlight for IXCHIQ by the US Food and Drug Administration (FDA), marking the approval of the world’s first chikungunya vaccine.

NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update - Vimarsana News

NRx Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update

Four near-term milestones, including initiation of potential spinout initiatives expected in 2023/early 2024 Completing enrollment of the originally-targeted...

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023 - Vimarsana News

89bio Announces Additional Data from the ENLIVEN Phase 2b Trial of Pegozafermin in Patients with Compensated Cirrhotic (F4) Nonalcoholic Steatohepatitis (NASH) at AASLD The Liver Meeting® 2023

—Reductions in key non-invasive tests of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated cirrhotic patients at week 24— —A...

89bio Announces Additional Data from the ENLIVEN Phase 2b - Vimarsana News

89bio Announces Additional Data from the ENLIVEN Phase 2b

—Reductions in key non-invasive tests (NITs) of liver inflammation and fibrosis support previously demonstrated fibrosis improvements across compensated...